MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.65
+0.03
+0.45%
After Hours: 6.65 0 0.00% 17:39 05/17 EDT
OPEN
6.57
PREV CLOSE
6.62
HIGH
6.72
LOW
6.45
VOLUME
3.36M
TURNOVER
--
52 WEEK HIGH
19.39
52 WEEK LOW
3.820
MARKET CAP
1.91B
P/E (TTM)
-6.9926
1D
5D
1M
3M
1Y
5Y
Sabby Management, Llc Buys Sorrento Therapeutics Inc, Second Sight Medical Products Inc, ...
GuruFocus News · 11h ago
Sorrento Therapeutics Study To Evaluate Intra-Articular Resiniferatoxin To Treat Moderate To Severe Pain From Knee Osteoarthritis Posted To Clinicaltrials Website
https://clinicaltrials.gov/ct2/show/NCT04885972
Benzinga · 4d ago
Sorrento Therapeutics US Patent & Trademark Office Abstract For Co.'s 'Variant Antibody That Binds Cd38'
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210130484%22.PGNR.&OS=DN/20210130484&RS=DN/2021
Benzinga · 05/06 14:16
10-Q: SORRENTO THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations This Quarterly Report on Form 10-Q...
Edgar Online - (EDG = 10Q, 10K) · 05/05 20:45
Moving Average Crossover Alert: Sorrento Therapeutics (SRNE)
Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Zacks · 05/05 12:09
Sorrento: The Monoclonal Antibody Portfolio Charges Ahead
TipRanks · 04/30 12:27
Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma
Benzinga · 04/27 18:30
Why Sorrento Therapeutics' Stock Is Trading Higher Today
Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher after the company received FDA clearance to proceed with its Phase 2 study for Sti-3031 in advanced urothelial carcinoma.
Benzinga · 04/27 17:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRNE stock price target is 27.50 with a high estimate of 35.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 276
Institutional Holdings: 88.90M
% Owned: 31.01%
Shares Outstanding: 286.65M
TypeInstitutionsShares
Increased
46
5.81M
New
23
472.12K
Decreased
42
2.08M
Sold Out
17
279.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Chief Financial Officer
Najjam Asghar
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
Edgar Lee
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
No Data
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.